Spots Global Cancer Trial Database for Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Official Title: An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment
Study ID: NCT01863745
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to collect and assess long-term safety of nilotinib in patients who are on nilotinib treatment in a Novartis-sponsored, Oncology CD\&MA study and are benefiting from the treatment as judged by the investigator.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Novartis Investigative Site, Nagoya, Aichi, Japan
Novartis Investigative Site, Kashiwa, Chiba, Japan
Novartis Investigative Site, Gifu-city, Gifu, Japan
Novartis Investigative Site, Sapporo city, Hokkaido, Japan
Novartis Investigative Site, Yokohama-city, Kanagawa, Japan
Novartis Investigative Site, Kumamoto City, Kumamoto, Japan
Novartis Investigative Site, Sendai city, Miyagi, Japan
Novartis Investigative Site, Kurashiki, Okayama, Japan
Novartis Investigative Site, Osaka-city, Osaka, Japan
Novartis Investigative Site, Suita, Osaka, Japan
Novartis Investigative Site, Chuo ku, Tokyo, Japan
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
